

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number:

**0 357 332 A3**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: 89308551.4

(51) Int. Cl.<sup>5</sup>: **A61K 37/64**, A61K 37/02,  
A61K 31/00, C07K 5/02

(22) Date of filing: **23.08.89**

(30) Priority: **24.08.88 US 235841**  
**28.03.89 US 328644**

(43) Date of publication of application:  
**07.03.90 Bulletin 90/10**

(84) Designated Contracting States:  
**AT BE CH DE ES FR GB IT LI LU NL SE**

(88) Date of deferred publication of the search report:  
**31.07.91 Bulletin 91/31**

(71) Applicant: **MERCK & CO. INC.**  
**126, East Lincoln Avenue P.O. Box 2000**  
**Rahway New Jersey 07065-0900(US)**

(72) Inventor: **Sigal, Irving S.**  
**Deceased**  
**Deceased(US)**  
Inventor: **Huff, Joel R.**  
**738 Bergey Mill Road**  
**Lederach, PA 19450(US)**  
Inventor: **Darke, Paul L.**  
**434 West Walnut Street**  
**North Wales, PA 19454(US)**

(74) Representative: **Hesketh, Alan, Dr. et al**  
**European Patent Department Merck & Co.,**  
**Inc. Terlings Park Eastwick Road**  
**Harlow Essex, CM20 2QR(GB)**

(54) **Renin inhibitors useful for the treatment of aids by inhibition of HIV protease.**

(57) Certain renin inhibitors are useful in the inhibition of HIV protease, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

**EP 0 357 332 A3**



European Patent  
Office

**PARTIAL EUROPEAN SEARCH REPORT**  
which under Rule 45 of the European Patent Convention  
shall be considered, for the purposes of subsequent  
proceedings, as the European search report

Application number  
**EP 89 30 8551**

<b>DOCUMENTS CONSIDERED TO BE RELEVANT</b>			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
X	NATURE, vol. 329, 15th October 1987, pages 654-656; I. KATOH et al.: "Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor"		A 61 K 437/64 A 61 K 437/02 A 61 K 431/00 C 07 K 5/02
	* Whole article, especially page 656, last paragraph *	1	
Y	--	2	
X	CELL, vol. 54, no. 3, 29th July 1988, pages 363-368, Cell Press; J. SCHNEIDER et al.: "Enzymatic activity of a synthetic 99 residue protein corresponding to the putative HIV-1 protease"		
	* Whole article *	1	
Y	--	2	
	./.		
			<b>TECHNICAL FIELDS SEARCHED (Int. Cl. 4)</b>
			A 61 K
<b>INCOMPLETE SEARCH</b>			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims.</p> <p>Claims searched completely: Claims searched incompletely: Claims not searched: Reason for the limitation of the search:</p> <p>See sheet -C-</p>			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>02-01-1991</b>	Examiner <b>ISERT</b>
<b>CATEGORY OF CITED DOCUMENTS</b>			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	



European Patent  
Office

### CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ All claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for all claims.
- ☐ Only part of the claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claims:
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

### X LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions,

namely:

See sheet -B-

- ☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☒ None of the further search fees has been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims: 1, 2



DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	SCIENCE, vol. 175, 1972, page 656; P. GROSS et al.: "Inhibition of the renin-angiotensinogen reaction by pepstatin"  * Whole article *  --	1	
P,X, Y	GB-A-2 203 740 (SANDOZ)  * Claims 1-3,5,6,8,10,11; page 17, line 16 - page 18, line 2 *  --	1-2	
D,Y	EP-A-0 156 322 (MERCK)  * Claims 1-5; pages 1-7 *  ----	2	TECHNICAL FIELDS SEARCHED (Int. Cl. 4)



### LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirement of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims 1,2: Use of an inhibitor or remin for the treatment of AIDS.
2. Claims 3-5: Use of a compound of the formula of claim 3 for the treatment of AIDS.
3. Claims 6-13,16: Compounds, pharmaceutical compositons comprising them and use thereof.